The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies.

Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.

The myasthenia gravis (MG) market across the 7MM is poised to grow at a CAGR of 11.1% from $4.5bn in 2024 to $13.0bn in 2034.

Formulation differentiates therapies in crowded markets by improving adherence, tolerability, convenience, and delivery efficiency.

Armed with oral administration and a cheaper price tag, Lipfendra is touted as a major advancement for patients.

The EC has approved an extended use of Johnson & Johnson's Tecvayli, along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).

Revolution Medicines’ breakthrough drug for pancreatic cancer was approved more than six months ahead of schedule.

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.